(b) minus any amount of utilised working capital loans;
(d) minus any amount which is overdue for payment with more than fourteen (14) days in connection with supply of assets or services;
(e) minus the amount of interest paid on the relevant Liquidity Testing Date;
(f) minus any amounts received as pre-payments, instalments or deposits by the Group from a client for any project to be carried out and delivered by the Group in the ordinary course of business, recorded in the balance sheet of the Group at the relevant Liquidity Testing Date;
(g) minus the amount of any equity cure injections made pursuant to the Senior Bank Facilities, which has been made to the Group during the last 12 months; and
(h) minus the amount of any proceeds raised during the last 12 months in connection with an Equity Listing Event which are not used to prepay the Bonds.
"Liquidity Testing Date" has the meaning set forth in Clause 12.1(a)(v) (Information from the Issuer).
"Market Loan" means any loan or other indebtedness where an entity issues commercial paper, certificates, subordinated debentures, bonds or any other debt securities (including, for the avoidance of doubt, medium term note programmes and other market funding programmes), provided in each case that such instruments and securities are or can be subject to trade on NASDAQ OMX Helsinki or any other regulated or unregulated recognised market place.
"Material Adverse Effect" means a material adverse effect on (a) the business, financial condition or operations of the Group taken as a whole, (b) the Issuer's ability to perform and comply with the undertakings set out in Clause 13 (General Undertakings), or (c) the validity or enforceability of these Terms and Conditions.
